SS Innovations International, Inc. — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On October 5, 2026, SS Innovations submitted its response to an FDA Additional Information Not-Enough (AINN) letter regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study and a bridging study completed in August 2026 at Hospital Internacional de Colombia. The company anticipates FDA review completion in Q1 2027 for the initial indication of cholecystectomy.
Why this rating
Regulatory milestone for core product; FDA approval critical to U.S. market entry and revenue generation. Material for $270M company, but approval not yet granted—meaningful progress but execution risk remains.
Tradability signal
NO TRADE
No trade: positive news with only -0.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.01% over 4 hrs, n=227). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $2.55 | +10 min · unknown $2.63 ▲ 3.10% | +30 min · unknown $2.60 ▲ 1.72% | +1 hr · unknown $2.63 ▲ 3.10% | +4 hrs · unknown $2.60 ▲ 1.92% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.